Trial · NCT01475825
Adverse events416
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 416
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Influenza like illness | General disorders | Regimen A: Mipomersen, 200 mg, Once Weekly | 43 | 104 | |
| other | Influenza like illness | General disorders | Regimen A: Placebo, Once Weekly | 10 | 51 | |
| other | Influenza like illness | General disorders | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 26 | 102 | |
| other | Influenza like illness | General disorders | Regimen B: Placebo, Thrice Weekly | 10 | 52 | |
| other | Injection site erythema | General disorders | Regimen A: Mipomersen, 200 mg, Once Weekly | 8 | 104 | |
| other | Injection site erythema | General disorders | Regimen A: Placebo, Once Weekly | 1 | 51 | |
| other | Injection site erythema | General disorders | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 13 | 102 | |
| other | Injection site erythema | General disorders | Regimen B: Placebo, Thrice Weekly | 1 | 52 | |
| other | Injection site pain | General disorders | Regimen A: Mipomersen, 200 mg, Once Weekly | 13 | 104 | |
| other | Injection site pain | General disorders | Regimen A: Placebo, Once Weekly | 1 | 51 | |
| other | Injection site pain | General disorders | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 7 | 102 | |
| other | Injection site pain | General disorders | Regimen B: Placebo, Thrice Weekly | 0 | 52 | |
| other | Injection site swelling | General disorders | Regimen A: Mipomersen, 200 mg, Once Weekly | 4 | 104 | |
| other | Injection site swelling | General disorders | Regimen A: Placebo, Once Weekly | 1 | 51 | |
| other | Injection site swelling | General disorders | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 8 | 102 | |
| other | Injection site swelling | General disorders | Regimen B: Placebo, Thrice Weekly | 1 | 52 | |
| other | Injection site pruritus | General disorders | Regimen A: Mipomersen, 200 mg, Once Weekly | 3 | 104 | |
| other | Injection site pruritus | General disorders | Regimen A: Placebo, Once Weekly | 1 | 51 | |
| other | Injection site pruritus | General disorders | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 7 | 102 | |
| other | Injection site pruritus | General disorders | Regimen B: Placebo, Thrice Weekly | 1 | 52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01475825/events